Top Pharmaceutical Companies in Boston, MA (130)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.
Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.
Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.
Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.
Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.
Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.
Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.
Ardelyx is a publicly traded biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed...
Advancing knowledge to improve lives.™ We are a global strategic partner with decades of experience across the entire life sciences product lifecycle. We excel in providing our clients with unique insights and efficiencies to support them in their journey to improve health outcomes and ultimately the quality of people’s lives. By connecting our full suite of products and services from scientific...
The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for people with cystic fibrosis, a rare, genetic disease in which a defective gene causes a thick buildup of mucus in the lungs, pancreas, and other organs. The buildup of mucus can lead to extensive lung damage, respiratory failure, malnutrition, liver disease, and gastrointestinal issues, among...
EVERSANA is the provider of global services to the life science industry.
EVERSANA's Top Stability & Growth Strengths
Strong Market Position & Advantage: Evidence indicates EVERSANA maintains a strong market position through its integrated, end-to-end commercialization model and a top-tier agency network. Feedback suggests exclusive launch mandates and consistent MM+M top‑10 agency rankings reinforce this competitive advantage.
Innovation-Driven Growth: Feedback suggests the company is investing in AI-enabled and software-driven offerings, including an AI Accelerator, an AI-powered marketing agency, and Waltz Health’s drug-pricing/access technology. These moves position the platform for tech-enabled growth across access, pricing, and omnichannel execution.
Market Expansion: Evidence indicates EVERSANA is expanding capacity and reach through a large new distribution center and a merger that extends influence with payers and employers. Ongoing commercialization wins and partnerships show continued entry into adjacent access and pricing markets.
Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. For more, please visit: bicara.com.
ProcDNA is a global analytics and technology consulting firm dedicated to delivering exceptional commercial analytics and technology solutions to the life sciences and healthcare sectors. Established in 2020, the company leverages a blend of design thinking, advanced data analytics, and AI to solve complex business challenges, transform data into commercial intelligence, and help pharmaceutical and biotechnology organizations achieve their goals...
.jpg)
SDC delivers top-tier clinical trial services to pharmaceutical, biologic, and medical device/diagnostic companies since 2005. We are committed to providing experienced teams who will take ownership of your needs and are positively engaged in your projects. With strategic scientific consulting and clinical data services (biostatistics, data management/EDC, and IRT/IWRS) expertise at our core, our services are scalable via our diverse...
YonaLink provides EHR-to-EDC streaming and AI-driven CRF mapping to assist with clinical trial data management and improve trial efficiency and data quality.
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes across oncology, neurology and cardiology. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years.
Lantheus's Top Stability & Growth Strengths
Strong Market Position & Advantage: PYLARIFY is described as the leading PSMA PET agent in the U.S., and DEFINITY is the most utilized ultrasound contrast agent, underscoring category leadership. Management’s 2026 plan emphasizes sustaining PSMA PET leadership and leveraging a broad manufacturing and distribution network.
Diversified Revenue Streams: Portfolio expansion into Alzheimer’s PET via NEURACEQ adds a second commercial PET pillar alongside PSMA and echocardiography contrast. Recent acquisitions and the SPECT divestiture concentrate the company around multiple higher‑growth PET diagnostics.
Future-Ready Strategy: FDA clearance of PYLARIFY TruVu with a phased 4Q26 launch is framed to expand capacity and strengthen supply. Management points to late‑stage catalysts and execution in 2026 as enablers of growth reacceleration from 2027.
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of...
Galderma is the leading company solely dedicated to skin and advancing the future of dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.
Dompé is an Italian bio-pharmaceutical company that focuses on innovation, where a long tradition in the field of personal wellness goes hand in hand with a commitment to research and development to meet hitherto unsatisfied therapeutic needs. Established in 1940 in Milan, Dompé continues to have its headquarters in this city. In Italy, it also has offices in L’Aquila, with an...
OM1 is an insights-driven technology and data company specializing in Personalized Medicine, Evidence Generation, and RWE Research powered by next-Gen A.I. platforms, regulatory-grade deep longitudinal data, and globally recognized thought leadership. Our unprecedented innovation takes RWE from Bench-to-Practice, delivering unparalleled personalized impact on the outcomes of patients and the advancement of research. We do things differently. We are pushing the boundaries...
We’re an innovative and forward-thinking Commercial Pharma analytics startup based in the UK. Since 2014 we’ve been focusing our efforts on providing cutting edge input to pharmaceutical organisations throughout Europe and North America. By combining years of experience in healthcare, pharmaceutical and data , we provide a powerful tool for acquiring real actionable insights to Commercial strategy, Formulary status, Salesforce...
We founded Precision Medicine Group in 2012 because we believed there was a transformational opportunity to improve the process of bringing new drugs to market. It involves utilizing technology, data, and human expertise. It is a big challenge that requires diverse talents. Our model involves both nurturing and investing organically and acquiring capabilities that we do not have but critically...
Precision Medicine Group's Top Stability & Growth Strengths
Strong Revenue Growth: Available information indicates revenue has scaled materially compared to earlier estimates, aligning with statements that the company is experiencing significant growth and expansion across multiple dimensions. This trajectory is framed alongside substantial capital accumulation and platform build-out.
Investor Backing & Capital Strength: The organization is described as having raised significant funding and completed a major private equity recapitalization, signaling strong capital support for continued expansion. Named investors and multi-round financing underscore capacity to invest in capabilities and global reach.
Market Expansion: Company updates highlight an active geographic build-out across APAC and Europe alongside U.S. lab expansions. Targeted acquisitions are cited as extending capabilities and regional presence, reinforcing an expanding global footprint.
Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area,...
Trinity Life Sciences is a modern partner to companies in the life sciences industry with nearly 30 years of expertise. The firm combines strategy, insights, and analytics to help life science executives with clinical and commercial decision-making. Serving over 300 pharmaceutical, biotech, and medical device clients, Trinity helps them develop the right drugs and devices for today’s market and optimize...
